Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 777,451 shares at $22.79 ($17.9M) on 2026-07-06, disclosed to the SEC on 2026-07-08.
Scheduled sale ($17.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.79 | 100,019 | $2.3M | 12.8% |
| 2 | $22.79 | 127,182 | $2.9M | 16.2% |
| 3 | $22.79 | 253,039 | $5.8M | 32.3% |
| 4 | $23.17 | 124,379 | $2.9M | 16.1% |
| 5 | $23.17 | 49,193 | $1.1M | 6.4% |
| 6 | $23.17 | 62,543 |
| $1.4M |
| 8.1% |
| 7 | $23.61 | 5,000 | $118K | 0.7% |
| 8 | $23.62 | 29,587 | $699K | 3.9% |
| 9 | $23.62 | 11,665 | $276K | 1.5% |
| 10 | $23.62 | 14,844 | $351K | 2.0% |
| Total | $22.97 avg | 777,451 | $17.9M | 100% |
| Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |
| DYN | SELL | 2026-04-30 | $4.2M | — | Filing → |